SCHEMBL21144446

SCHEMBL21144446

Cc1csc(-c2nc(Cl)cc(NC3CCCCC3=O)n2)n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 11/20 0.33
FABP5 Q01469 11/20 0.33
GRM5 P41594 3/20 0.33
RAB9A P51151 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
CDC7 O00311 1/20 0.31
CHEK1 O14757 1/20 0.31
MAPK13 O15264 1/20 0.31
PDPK1 O15530 1/20 0.31
DAPK3 O43293 1/20 0.31
DYRK3 O43781 1/20 0.31
PAK4 O96013 1/20 0.31
CHEK2 O96017 1/20 0.31
EGFR P00533 1/20 0.31
PRKCG P05129 1/20 0.31
CDK1 P06493 1/20 0.31
LYN P07948 1/20 0.31
ROS1 P08922 1/20 0.31
FER P16591 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31127388 1.00 FABP4 (0.33) FABP4FABP5GRM5RAB9AADORA2A
SCHEMBL21143971 0.82 CDC7 (0.46) RAB9AADORA2AADORA1CDC7CHEK1
SCHEMBL19686738 0.80 IRAK4 (0.41) ADORA2AADORA1IRAK4ALDH1A1
SCHEMBL31127059 0.80 IRAK4 (0.41) ADORA2AADORA1IRAK4ALDH1A1
SCHEMBL21143910 0.79 CDC7 (0.34) ADORA2AADORA1CDC7CHEK1MAPK13
SCHEMBL21143659 0.78 IDH1 (0.37) RAB9AADORA2AADORA1CDC7CHEK1
SCHEMBL31127080 0.78 IDH1 (0.37) RAB9AADORA2AADORA1CDC7CHEK1
SCHEMBL21143868 0.78 SCN9A (0.34) RAB9AADORA2AADORA1CDC7CHEK1
SCHEMBL21143784 0.76 PTGS2 (0.40) ADORA2AADORA1CDC7CHEK1MAPK13
SCHEMBL21144045 0.75 IDH1 (0.38) FABP4FABP5ADORA2AADORA1CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 FABP4 2531/4885FABP5 2779/4885GRM5 1096/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 FABP4 2531/4885FABP5 2779/4885GRM5 1096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.